Typhoid conjugate Vaccine
ApprovedVaccine
SanofiTyphoid conjugate Vaccine is one of 51 biologic programs targeting Malnutrition. It is currently in Approved.
2
Indications
6
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Typhoid conjugate Vaccine
SanofiApproved
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Piperaquine
UUniversity of Oxford
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vaccine2 trials
Vellore Typhoid Vaccine Impact Trial
Completed·—·Phase 4·NCT05500482·72,400 enrolled
Pediatric1 trial
Unspecified1 trial
Co-administration Study of OCV, TCV and MR
Unknown status·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 3·NCT05771779·2,117 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Typhoid conjugate Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]